All In Biotech

Drug Trial Radar · NCT07594509

Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery

A Multicenter, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery

Last checked: Nov 20, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

May 31, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Nanjing Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing Anzhen Hospital; The Affiliated Hospital of Qingdao University; Changzhou First People's Hospital; The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Bengbu Medical University; West China Hospital; Shanghai East Hospital
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of perioperative vericiguat in patients undergoing cardiovascular surgery. Patients at high risk of heart failure or with confirmed cardiac dysfunction will be randomly assigned to receive either vericiguat plus standard of care or standard of care alone. The primary objective is to determine whether perioperative administration of vericiguat can reduce (I) the Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial Injury; (II) Incidence of Major Sterile Inflammation-Related Organ Injuries (MSIRI), and the incidence of Major Adverse Cardiovascular Events (MACE) within 12 months after surgery.

Conditions

  • Cardio Vascular Disease
  • Cardiopulmonary Bypass

Interventions

  • VericiguatDrug

    Patients will receive oral vericiguat in addition to standardized perioperative care. Vericiguat will be initiated 3 days before surgery at a dose of 2.5 mg once daily. Postoperatively, upon resumption of enteral nutrition, vericiguat will be continued and gradually up-titrated every 2 weeks based on blood pressure tolerability to 5 mg, and then to a target dose of 10 mg once daily, taken with food, for a total duration of 1 months.

  • Standard of Care GroupDrug

    Patients will receive standardized perioperative cardiovascular surgery care alone, without vericiguat or placebo. Standard care includes preoperative preparation, postoperative monitoring, anti-infection, antiplatelet/anticoagulation, diuretics, beta-blockers, SGLT2 inhibitors, and other symptomatic treatments for heart failure according to current guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial InjuryTime frame: Up to 7 days postoperatively (or until ICU discharge, whichever comes first).
  2. Incidence of Major Adverse Cardiovascular Events (MACE)Time frame: Up to 6 months postoperatively
  3. Incidence of Major Sterile Inflammation-Related Organ Injuries (MSIRI)Time frame: Up to 7 days postoperatively.
  4. Maximum Sequential Organ Failure Assessment (SOFA) ScoreTime frame: Up to 7 days postoperatively.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.